Nerisona (Diflucortolone Valerate)

Diflucortolone valerate, the active ingredient in Nerisona, is a corticosteroid presented as a topical formulation for cutaneous use. It is employed to reduce inflammation and relieve symptoms in various skin disorders such as eczema, psoriasis and dermatitis.

GNH USA supplies Nerisona as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Diflucortolone valerate is a topical corticosteroid used to manage inflammatory skin conditions.

- Eczema: reduces redness, swelling and itching associated with atopic dermatitis. - Psoriasis: diminishes plaque formation and scaling in plaque psoriasis. - Dermatitis: alleviates irritation and inflammation in contact or seborrheic dermatitis. - Other inflammatory skin disorders: provides symptomatic relief in various chronic inflammatory dermatoses.

Topical diflucortolone valerate may cause local adverse reactions, most of which are mild and reversible.

Common Side Effects: - Burning or stinging at the application site. - Pruritus or mild itching. - Dryness or flaking of the skin. - Erythema or mild redness. - Folliculitis or small pustules. - Telangiectasia (visible small blood vessels).

Serious or Rare Side Effects: - Skin atrophy or thinning with prolonged use. - Striae (stretch marks) formation. - Secondary bacterial, fungal or viral skin infections. - Hypersensitivity reactions such as contact dermatitis. - Systemic absorption leading to adrenal suppression (rare). - Delayed wound healing.

Before using diflucortolone valerate, consider the following safety measures.

- Avoid prolonged use on large surface areas: limit duration to reduce risk of systemic effects. - Do not apply to infected or ulcerated skin: may worsen infection. - Use with caution in children: higher per‑kg absorption can increase adverse effects. - Discontinue if severe irritation or allergic reaction occurs: seek medical advice. - Avoid occlusive dressings unless directed: can enhance drug penetration. - Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Diflucortolone valerate can interact with other agents that affect skin integrity or systemic corticosteroid exposure.

Major Interactions (Avoid): - Systemic corticosteroids: concurrent use may increase risk of systemic glucocorticoid effects. - Potent immunosuppressants (e.g., tacrolimus, cyclosporine): may heighten infection risk. - Antifungal or antibacterial topical agents on the same area: can alter absorption and increase irritation.

Moderate Interactions (Monitor Closely): - Skin‑lightening agents (hydroquinone): may increase irritation. - Retinoids (topical or oral): potential for additive skin irritation. - Non‑steroidal anti‑inflammatory drugs (topical): monitor for enhanced local reactions.